secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0000950170-24-113524
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology CFO Nathan Hardy resigns; CEO Harr named acting PFO, Susan Wyrick acting CFO
--------------------------------------------------------------------------------

- CFO Nathan Hardy resigned effective Oct 4, 2024; acting appointments made same day.
- CEO Steven D. Harr appointed acting Principal Financial Officer; no compensation change.
- Susan Wyrick appointed Acting CFO, Treasurer, and PAO; receives $5k/month extra, $25k bonus, 20,000 RSUs.
- Wyrick previously SVP Finance; former VP Controller at Juno Therapeutics prior to Celgene acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024113524/0000950170-24-113524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024113524/sana-20241004.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer